Compare Amgen, Inc. (AMGN) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Vistra Corp — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Vistra Corp trades at $157.34 (market cap $53.56B). The key difference: Amgen, Inc. is far larger — about 3.7× Vistra Corp's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | VST | |
|---|---|---|
Market Cap | $196.12B | $53.56B |
Sector | Health | Technology |
52-Week High | $388.16 | $217.92 |
52-Week Low | $271.18 | $134.71 |
Enterprise Value | $241.41B | $75.32B |
Dividend Yield | 2.77% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Vistra Corp. (VST) trades at $158.86, up 0.56% today, with a bullish technical outlook supported by moving averages and a neutral RSI. The company reported strong Q1 2026 earnings beat but missed Q3 and Q4 2025 estimates. Revenue grew to $19.4B in 2026 with net profit margin improving to 11.52%. Recent news highlights AI-driven power demand and long-term PPAs with Meta and AWS as growth catalysts.
Outlook is positive with 91% analyst buy ratings and a $230.50 consensus price target, implying 45% upside. Risks include execution on growth initiatives and macroeconomic volatility. The stock offers exposure to rising electricity demand and stable cash flows from utility operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
